Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice [PDF]
Journal of Pharmacological Sciences, 2019 Oxaliplatin, a platinum-based chemotherapeutic drug, frequently induces peripheral neuropathy. Accumulating evidences suggest a possible relationship between peripheral vascular impairment and peripheral neuropathy.
Takashi Ogihara +9 more
doaj +3 more sources
CLINICAL CASE: THERAPY WITH SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION [PDF]
Евразийский Кардиологический Журнал, 2015 The patient with the verified diagnosis of idiopathic pulmonary hypertension, negative acute vasoreactivity testing by RHC, functional class III (WHO) was treated by phosphodiesterase type 5 inhibitor sildenafil.
Z. S. Valieva +5 more
doaj +3 more sources
Phosphodiesterase type 5 inhibitor (Levitra): possibility of correction of erectile dysfunction in obese patients [PDF]
Ожирение и метаболизм, 2008 Obesity is the cause of a number of diseases such as type 2 diabetes, hypertension, atherosclerosis and coronary heart disease [1]. Obesity is associated with the development of a number of hormone-dependent tumors (breast cancer, uterine cancer) and ...
doaj +2 more sources
Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction [PDF]
Therapeutic Advances in Urology, 2009 Phosphodiesterase type 5 inhibitors (PDE5-i) have become first line therapy for the treatment of erectile dysfunction. Most initial prescriptions for PDE5-i are by primary care practitioners.
Gregory Lowe MD, Robert Bahnson
doaj +2 more sources
Penile microvascular endothelial function in hypertensive patients: effects of acute type 5 phosphodiesterase inhibition [PDF]
Brazilian Journal of Medical and Biological Research, 2018 The primary aim of this study was to evaluate penile endothelial microvascular function in patients with primary arterial hypertension and age-matched normotensive subjects using laser speckle contrast imaging (LSCI).
V. Verri, A.A. Brandão, E. Tibirica
doaj +2 more sources
The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species. [PDF]
Antioxidants (Basel), 2020 Systemic sclerosis (SSc) is a multi-system connective tissue disease characterized by the increased deposition of extracellular matrix proteins such as collagen and fibronectin.
Di Luigi L +11 more
europepmc +3 more sources
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment. [PDF]
Eur Urol, 2016 Background: Phosphodiesterase type 5 inhibitor (PDE5i) use is common for management of erectile dysfunction. Single-institution studies have reported conflicting data on the relationship between PDE5i use and biochemical recurrence of prostate cancer ...
Loeb S +5 more
europepmc +2 more sources
Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line. [PDF]
Int J Mol Sci, 2021 Background: The androgen receptor (AR) plays a key role in normal prostate homeostasis and in prostate cancer (PCa) development, while the role of aromatase (Cyp19a1) is still unclear.
Bimonte VM +11 more
europepmc +3 more sources
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. [PDF]
Heart, 2016 Objective Experimental evidence has shown potential cardioprotective actions of phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether phosphodiesterase type-5 inhibitor (PDE5i) use in patients with type 2 diabetes, with high attendant ...
Anderson SG +8 more
europepmc +3 more sources
The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis. [PDF]
Sex Med, 2018 Introduction: Phosphodiesterase type 5 inhibitors (PDE5-Is) are first-line drugs for erectile dysfunction. Non-arteritic anterior ischemic optic neuropathy (NAION) has been linked with PDE5-I use.
Liu B, Zhu L, Zhong J, Zeng G, Deng T.
europepmc +2 more sources